Drug Profile
Gildeuretinol - Alkeus Pharmaceuticals/Columbia University
Alternative Names: ALK-001; C20-D3-Retinyl Acetate; C20-D3-vitamin A; Deuterated-retinol; Deuterated-vitamin-A; Vitamin-A-deuteratedLatest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Alkeus Pharmaceuticals
- Class Eye disorder therapies; Retinoids; Vitamins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Dry age-related macular degeneration
- Phase II Stargardt disease
- No development reported Retinal dystrophies
Most Recent Events
- 21 Dec 2023 Alkeus Pharmaceuticals completes a phase-II/III clinical trials in Dry age-related macular degeneration (In adults, In the elderly) in USA (PO) (NCT03845582)
- 05 Jun 2023 Alkeus Pharmaceuticals announces intention to submit an NDA to US FDA for Stargardt disease in 2024
- 05 Jun 2023 Efficacy and adverse events data from a phase II trial in Stargardt disease released by Alkeus Pharmaceuticals